Journal of Traditional Chinese Medicine ›› 2024, Vol. 44 ›› Issue (6): 1137-1145.DOI: 10.19852/j.cnki.jtcm.2024.06.004
• Research Articles • Previous Articles Next Articles
TANG Weiwei1(), LIU Kaili1, FAN Xumei1, ZHU Li1, ZENG Zheng2, SUN Jiali1, SHI Jie1, ZHANG Zhenzhen1, GUI Tao1, WAN Guiping1
Received:
2023-11-11
Accepted:
2024-05-27
Online:
2024-12-15
Published:
2024-11-12
Contact:
TANG Weiwei
About author:
TANG Weiwei, Department of Obstetrics and Gynecology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China. tangweiwei3201@163.com Telephone: +86-15996250632Supported by:
TANG Weiwei, LIU Kaili, FAN Xumei, ZHU Li, ZENG Zheng, SUN Jiali, SHI Jie, ZHANG Zhenzhen, GUI Tao, WAN Guiping. Bushen Huoxue decoction (补肾活血汤) improves the reproduction of endometriosis-associated infertility by regulating Homeobox A10 and αlpha(v)beta(3) integrin expression[J]. Journal of Traditional Chinese Medicine, 2024, 44(6): 1137-1145.
Num | Compound | RT (min) | Molecular weight (Da) | Formula | Ionization model | Class I | Class II |
---|---|---|---|---|---|---|---|
1 | Cryptochlorogenic acid (4-O-Caffeoylquinic acid) | 2.79 | 3.54E+02 | C16H18O9 | [M-H]- | Phenolic acids | Phenolic acids |
2 | N-Feruloylagmatine | 2.91 | 3.06E+02 | C15H22N4O3 | [M+H]+ | Alkaloids | Phenolamine |
3 | 3,4-Dihydroxybenzoic acid (Protocatechuic acid) | 2.58 | 1.54E+02 | C7H6O4 | [M-H]- | Phenolic acids | Phenolic acids |
4 | Protocatechualdehyde | 3.12 | 1.38E+02 | C7H6O3 | [M-H]- | Others | Aldehyde compounds |
5 | Luteolin-4'-O-glucoside | 4.06 | 4.48E+02 | C21H20O11 | [M+H]+ | Flavonoids | Flavones |
6 | Brevifolin carboxylic acid | 3.05 | 2.92E+02 | C13H8O8 | [M-H]- | Phenolic acids | Phenolic acids |
7 | Gallic acid | 1.81 | 1.70E+02 | C7H6O5 | [M-H]- | Phenolic acids | Phenolic acids |
8 | Paeonilactone C | 4.34 | 3.18E+02 | C17H18O6 | [M+H]+ | Terpenoids | Monoterpenoids |
9 | Quercetin-5-O-β-D-glucoside | 3.82 | 4.64E+02 | C21H20O12 | [M+H]+ | Flavonoids | Flavonols |
10 | Quercetin-3-O-glucoside (Isoquercitrin) | 3.82 | 4.64E+02 | C21H20O12 | [M+H]+ | Flavonoids | Flavonols |
11 | Cistanoside A | 3.48 | 8.00E+02 | C36H48O20 | [M-H]- | Phenolic acids | Phenolic acids |
12 | Luteolin-7-O-glucoside (Cynaroside) | 4.09 | 4.48E+02 | C21H20O11 | [M+H]+ | Flavonoids | Flavones |
13 | Kaempferol-4'-O-glucoside | 4.05 | 4.48E+02 | C21H20O11 | [M+H]+ | Flavonoids | Flavonols |
14 | Quercetin-3-O-galactoside (Hyperin) | 3.82 | 4.64E+02 | C21H20O12 | [M+H]+ | Flavonoids | Flavonols |
15 | Saikosaponin A | 6.37 | 7.80E+02 | C42H68O13 | [M-H]- | Terpenoids | Triterpene Saponin |
16 | Isoferulic Acid | 4.03 | 1.94E+02 | C10H10O4 | [M-H]- | Phenolic acids | Phenolic acids |
17 | Echinacoside | 3.19 | 7.86E+02 | C35H46O20 | [M-H]- | Phenolic acids | Phenolic acids |
18 | Saikogenin Q | 5.54 | 4.88E+02 | C30H48O5 | [M+H]+ | Terpenoids | Triterpene |
19 | Calycosin-7-O-glucoside | 3.56 | 4.46E+02 | C22H22O10 | [M+H]+ | Flavonoids | Isoflavones |
20 | Catalpol | 1.19 | 3.62E+02 | C15H22O10 | [M-H]- | Terpenoids | Monoterpenoids |
Table 1 Main components of Bushen Huoxue decotion identified by high performance liquid chromatography-mass spectrometry (HPLC-MS/MS)
Num | Compound | RT (min) | Molecular weight (Da) | Formula | Ionization model | Class I | Class II |
---|---|---|---|---|---|---|---|
1 | Cryptochlorogenic acid (4-O-Caffeoylquinic acid) | 2.79 | 3.54E+02 | C16H18O9 | [M-H]- | Phenolic acids | Phenolic acids |
2 | N-Feruloylagmatine | 2.91 | 3.06E+02 | C15H22N4O3 | [M+H]+ | Alkaloids | Phenolamine |
3 | 3,4-Dihydroxybenzoic acid (Protocatechuic acid) | 2.58 | 1.54E+02 | C7H6O4 | [M-H]- | Phenolic acids | Phenolic acids |
4 | Protocatechualdehyde | 3.12 | 1.38E+02 | C7H6O3 | [M-H]- | Others | Aldehyde compounds |
5 | Luteolin-4'-O-glucoside | 4.06 | 4.48E+02 | C21H20O11 | [M+H]+ | Flavonoids | Flavones |
6 | Brevifolin carboxylic acid | 3.05 | 2.92E+02 | C13H8O8 | [M-H]- | Phenolic acids | Phenolic acids |
7 | Gallic acid | 1.81 | 1.70E+02 | C7H6O5 | [M-H]- | Phenolic acids | Phenolic acids |
8 | Paeonilactone C | 4.34 | 3.18E+02 | C17H18O6 | [M+H]+ | Terpenoids | Monoterpenoids |
9 | Quercetin-5-O-β-D-glucoside | 3.82 | 4.64E+02 | C21H20O12 | [M+H]+ | Flavonoids | Flavonols |
10 | Quercetin-3-O-glucoside (Isoquercitrin) | 3.82 | 4.64E+02 | C21H20O12 | [M+H]+ | Flavonoids | Flavonols |
11 | Cistanoside A | 3.48 | 8.00E+02 | C36H48O20 | [M-H]- | Phenolic acids | Phenolic acids |
12 | Luteolin-7-O-glucoside (Cynaroside) | 4.09 | 4.48E+02 | C21H20O11 | [M+H]+ | Flavonoids | Flavones |
13 | Kaempferol-4'-O-glucoside | 4.05 | 4.48E+02 | C21H20O11 | [M+H]+ | Flavonoids | Flavonols |
14 | Quercetin-3-O-galactoside (Hyperin) | 3.82 | 4.64E+02 | C21H20O12 | [M+H]+ | Flavonoids | Flavonols |
15 | Saikosaponin A | 6.37 | 7.80E+02 | C42H68O13 | [M-H]- | Terpenoids | Triterpene Saponin |
16 | Isoferulic Acid | 4.03 | 1.94E+02 | C10H10O4 | [M-H]- | Phenolic acids | Phenolic acids |
17 | Echinacoside | 3.19 | 7.86E+02 | C35H46O20 | [M-H]- | Phenolic acids | Phenolic acids |
18 | Saikogenin Q | 5.54 | 4.88E+02 | C30H48O5 | [M+H]+ | Terpenoids | Triterpene |
19 | Calycosin-7-O-glucoside | 3.56 | 4.46E+02 | C22H22O10 | [M+H]+ | Flavonoids | Isoflavones |
20 | Catalpol | 1.19 | 3.62E+02 | C15H22O10 | [M-H]- | Terpenoids | Monoterpenoids |
Figure 1 BSHXD promotes embryo attachment in vitro and in vivo A: adhesion experiments with BeWo spheroids attached to Ishikawa cell monolayers. The attached spheroids were counted and the attachment rate was calculated as a percentage of the total number of BeWo spheroids (% adhesion). Data were presented as mean ± standard deviation (n = 4). B: endometriosis mouse models were treated with dydrogesterone and different dose BSHXD. After 28 d treatment, the mice were mated. The pregnant mice were euthanized on the 14th day of gestation and total number of embryos was calculated. Statistical analysis was carried out using ANOVA tests among these groups. Data were presented as mean ± standard deviation (n = 7) C: Mouse embryo (black arrow) attached to Ishikawa cells (× 100). D: Adhesion experiments of mouse embryos attached to the Ishikawa cell monolayer. The attachment score of each group was described as median with the interquartile range (n = 5). In Figures A and D: Control group: Ishikawa cell cultured in basal medium; Dydrogesterone group: Ishikawa cell cultured in presence of 10 nmol/L dydrogesterone; Low dose BSHXD group: Ishikawa cell cultured in presence of 5% BSHXD serum; Normal dose BSHXD group: Ishikawa cell cultured in presence of 10% BSHXD serum; High dose BSHXD group: Ishikawa cell cultured in presence of 20% BSHXD serum. In Figure B: Control group: sham surgery mice were treated with water; Model group: endometriosis mouse models were treated with water; Dydrogesterone group: endometriosis mouse models were treated with dydrogesterone (3.03 mg·kg-1·d-1); Low dose BSHXD group: endometriosis mouse models were treated with low dose BSHXD (6.218 g·kg-1·d-1); Normal dose BSHXD group: endometriosis mouse models were treated with normal dose BSHXD (12.437 g·kg-1·d-1); High dose BSHXD group: endometriosis mouse models were treated with high dose BSHXD (24.873 g·kg-1·d-1). BSHXD: Bushen Huoxue decotion; ANOVA: analysis of variance. Statistical analysis was carried out using Kruskal-Wallis with Dunn’s multiple comparison tests among these groups. Compared with the Control group, aP < 0.05; compared with the Model group, bP < 0.01.
Figure 2 BSHXD induces HOXA10 and αvβ3 integrin expression in Ishikawa cells A: Ishikawa cells were treated with Dydrogesterone and different dose BSHXD serum for 24 h and the level of HOXA10 and ITGB3 were detected using RT-qPCR; B: Expression of HOXA10 and αvβ3 integrin were detected by western blotting; C: HOXA10 expression of western blotting was quantitated by using Image J software; D: αvβ3 integrin expression of western blotting was quantitated. Control group: Ishikawa cell cultured in basal medium; Dydrogesterone group: Ishikawa cell cultured in presence of 10 nmol/L dydrogesterone; Low dose BSHXD group: Ishikawa cell cultured in presence of 5% BSHXD serum; Normal dose BSHXD group: Ishikawa cell cultured in presence of 10% BSHXD serum; High dose BSHXD group: Ishikawa cell cultured in presence of 20% BSHXD serum. BSHXD: Bushen Huoxue decotion; HOXA10: Homeobox A10; αvβ3: alpha(v)beta(3) integrin; ITGB3: integrin beta(3); RT-qPCR: real-time quantitative polymerase chain reaction; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; ANOVA: analysis of variance. ANOVA tests were used among these groups. Data were presented as mean ± standard deviation (n = 3). Compared with the Control group, aP < 0.05; compared with the Low dose group, bP < 0.05; compared with the Nomal dose dose group, cP < 0.05.
Figure 3 BSHXD increases HOXA10 and αvβ3 integrin expression in endometriosis mouse model A: endometriosis mouse models were treated with dydrogesterone and different dose BSHXD, after 28 d treatment, the mice were mated. The pregnant mice were euthanized on the 14th day of gestation and the endometrium was subjected to immunohistochemical staining using HOXA10 antibody (× 100). A1: Control group; A2: Model group; A3: Dydrogesterone group; A4: Low dose BSHXD group; A5: Normal dose BSHXD group; A6: High dose BSHXD group. B: The endometrium was subjected to immunohistochemical staining using αvβ3 integrin antibody (× 100). B1: Control group; B2: Model group; B3: Dydrogesterone group; B4: Low dose BSHXD group; B5: Normal dose BSHXD group; B6: High dose BSHXD group. C: the intensity of HOXA10 staining was quantitated by using Image J software. D: the intensity of αvβ3 integrin staining was quantitated. E: the expression level of Hoxa10 was determined using RT-qPCR. F: the expression level of Itgb3 was determined by RT-qPCR. Control group: sham surgery mice were treated with water; Model group: endometriosis mouse models were treated with water; Dydrogesterone group: endometriosis mouse models were treated with dydrogesterone (3.03 mg·kg-1·d-1); Low dose BSHXD group: endometriosis mouse models were treated with low dose BSHXD (6.218 g·kg-1·d-1); Normal dose BSHXD group: endometriosis mouse models were treated with normal dose BSHXD (12.437 g·kg-1·d-1); High dose BSHXD group: endometriosis mouse models were treated with high dose BSHXD (24.873 g·kg-1·d-1). BSHXD: Bushen Huoxue decotion; HOXA10: Homeobox A10; αvβ3: alpha(v)beta(3) integrin; Itgb3: Integrin beta(3); RT-qPCR: real-time quantitative polymerase chain reaction; D-HSCORE: digital histological score; mRNA: messenger ribonucleic acid; ANOVA: analysis of variance. Statistical analysis was carried out using ANOVA tests among these groups. Data were presented as mean ± standard deviation (n = 7). Compared with the model group, aP < 0.05.
Figure 4 BSHXD induces HOXA10 and αvβ3 integrin expression in endometriosis-associated infertility women A: The mid-secretory endometrial biopsy specimens were obtained from twenty endometriosis-associated infertility women before and after BSHXD treatment for three menstrual cycles and were subjected to immunohistochemical staining by using HOXA10 antibody (×100). A1: Control group; A2: BSHXD group. B: The intensity of HOXA10 staining was quantitated by using Image J software. Control group: patients not treated with BSHXD; BSHXD group: patients treated with BSHXD (82 g/d) for three menstrual cycles. BSHXD: Bushen Huoxue decotion; ELISA: enzyme-linked immunosorbent assay; D-HSCORE: digital histological score. Student’s t-tests were used for comparisons of two groups. Data were presented as mean ± standard deviation (n = 20). Compared with the control group, aP < 0.05.
1. | Ye L, Whitaker LHR, Mawson RL, Hickey M. Endometriosis. BMJ 2022; 379: e068950. |
2. |
Pirtea P, Vulliemoz N, De Ziegler D, Ayoubi JM. Infertility workup: identifying endometriosis. Fertil Steril 2022; 118: 29-33.
DOI PMID |
3. | Qu H, Du Y, Yu Y, et al. The effect of endometriosis on Ivf/Icsi and perinatal outcome: a systematic review and Meta-analysis. J Gynecol Obstet Hum Reprod 2022; 51: 102446. |
4. |
Munro MG. Uterine polyps, adenomyosis, leiomyomas, and endometrial receptivity. Fertil Steril 2019; 111: 629-40.
DOI PMID |
5. | Guo SW. Genesis, genes and epigenetics of endometriosis-associated infertility. Nat Rev Endocrinol 2019; 15: 259-60. |
6. |
Naqvi H, Mamillapalli R, Krikun G, Taylor HS. Endometriosis located proximal to or remote from the uterus differentially affects uterine gene expression. Reprod Sci 2016; 23: 186-91.
DOI PMID |
7. | Tang WW, Zhu L, Huang MH, Liu KL, Wan GP. Influence of bushen huoxue decoction on Il-6 and Lif expression in uterine flushing fluid of endometriosis. Jilin Zhong Yi Yao 2018; 38:1285-7. |
8. | Song Y, Zhou F, Tan X, et al. Bushen huoxue recipe attenuates early pregnancy loss via activating endometrial cox2-pge 2 angiogenic signaling in mice. BMC Complement Med Ther 2021; 21: 36. |
9. | Xue P, Zhou W, Fan W, et al. Increased mettl3-mediated m(6)a methylation inhibits embryo implantation by repressing Hoxa10 expression in recurrent implantation failure. Reprod Biol Endocrinol 2021; 19: 187. |
10. |
Tang W, Jiang Y, Mu X, et al. Mir-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates Hoxa10 expression. Cell Signal 2014; 26: 1420-6.
DOI PMID |
11. |
Tang W, Ramasamy K, Pillai SMA, et al. Lif/lifr oncogenic signaling is a novel therapeutic target in endometrial cancer. Cell Death Discov 2021; 7: 216.
DOI PMID |
12. | You F, Cao J, Cheng L, Liu X, Zeng L. Hyperin alleviates triptolide-induced ovarian granulosa cell injury by regulating Akt/Tsc1/Mtorc1 signaling. Evid Based Complement Alternat Med 2021; 2021: 9399261. |
13. | Li X, Zhou D, Yang D, et al. Isoquercitrin attenuates osteogenic injury in Mc3t 3 osteoblastic cells and the zebrafish model via the Keap1-Nrf2-Are pathway. Molecules 2022; 27: 3459. |
14. | Bouyahya A, Taha D, Benali T, et al. Natural sources, biological effects, and pharmacological properties of cynaroside. Biomed Pharmacother 2023; 161: 114337. |
15. | Park KS, Kim H, Kim HJ, et al. Paeoniflorin alleviates skeletal muscle atrophy in ovariectomized mice through the Erα/Nrf 1 mitochondrial biogenesis pathway. Pharmaceuticals (Basel) 2022; 15: 390. |
16. |
Haas J, Casper RF. Observations on clinical assessment of endometrial receptivity. Fertil Steril 2022; 118: 828-31.
DOI PMID |
17. |
Alecsandru D, Garcia Velasco JA. The excessive presence (percentage or number) of endometrial immune cells in patients with chronic endometritis cannot be associated with reduced endometrial receptivity or recurrent pregnancy failure. Fertil Steril 2020; 113: 85-6.
DOI PMID |
18. | Esfandiari F, Chitsazian F, Jahromi MG, et al. Hox cluster and their cofactors showed an altered expression pattern in eutopic and ectopic endometriosis tissues. Reprod Biol Endocrinol 2021; 19: 132. |
19. | Casale M. Improving the health and treatment success rates of in vitro fertilization patients with Traditional Chinese Medicine: need for more robust evidence and innovative approaches. J Integr Med 2022; 20: 187-92. |
20. |
Cao Y, Chen Y, Wang P, et al. Network pharmacology and experimental validation to explore the molecular mechanisms of Bushen Huoxue for the treatment of premature ovarian insufficiency. Bioengineered 2021; 12: 10345-62.
DOI PMID |
21. |
Ma K, Yuan Y, Chen YX, et al. Efficacy of Bushen Culuan decoction on ovarian follicle and follicular granulosa cells in mice with premature ovarian insufficiency induced by tripterygium wilfordii polyglycoside. J Tradit Chin Med 2022; 42: 23-9.
PMID |
22. | Wu K, Zhao X, Xiao X, et al. Bushen huoxue decoction improves fertility through intestinal hsp-16.2-mediated heat-shock signaling pathway in caenorhabditis elegans. Front Pharmacol 2023; 14: 1210701. |
23. | Wu H, Wu P, Zhu Y, et al. Bushen huoxue recipe inhibits endometrial epithelial-mesenchymal transition through the transforming growth factor-Β/nuclear factor kappa-B pathway to improve polycystic ovary syndrome-mediated infertility. Gynecol Endocrinol 2024; 40: 2325000. |
24. | You XM, Xu JB, Yang J, Liao J. Clinical efficacy of acupuncture combined with chinese herbal medication for recurrent implantation failure infertility of kidney deficiency and blood stasis and its effects on serum P38mapk and Jak/stat protein expression. Zhong Guo Zhen Jiu 2023; 43: 1399-404. |
25. | Du H, Taylor HS. The Role of Hox genes in female reproductive tract development, adult function, and fertility. Cold Spring Harb Perspect Med 2015; 6: a023002. |
26. |
Wang M, Hao C, Huang X, et al. Aberrant expression of lncrna ( Hoxa11-As1) and Homeobox a ( Hoxa9, Hoxa10, Hoxa11, and Hoxa13) genes in infertile women with endometriosis. Reprod Sci 2018; 25: 654-61.
DOI PMID |
27. | Ekanayake DL, Małopolska MM, Schwarz T, Tuz R, Bartlewski PM. The roles and expression of Hoxa/Hoxa10 gene: a prospective marker of mammalian female fertility? Reprod Biol 2022; 22: 100647. |
28. | Cheng J, Li C, Ying Y, et al. Metformin alleviates endometriosis and potentiates endometrial receptivity via decreasing vegf and mmp9 and increasing leukemia inhibitor factor and Hoxa10. Front Pharmacol 2022; 13: 750208. |
29. | Yan Q, Huang C, Jiang Y, et al. Calpain7 impairs embryo implantation by downregulating Β3-integrin expression via degradation of Hoxa10. Cell Death Dis 2018; 9: 291. |
30. | Fukui Y, Hirota Y, Aikawa S, et al. Uterine receptivity is reflected by Lif expression in the cervix. Reprod Sci 2022; 29: 1457-62. |
31. |
Marron K, Harrity C, Dunne H, Shkrobot L, Kennedy J. Cytometric assessment of uterine receptivity via epithelial Β3 integrin expression. Reprod Biomed Online 2019; 39: 294-303.
DOI PMID |
32. | Dokuzeylül Güngör N, Önal M, Madenli AA, Ağar M. Surgical removal of Figo type 0 and 1 fibroids ameliorates the expression of endometrial proinflammatory transcription factors and receptivity modulators. Fertil Steril 2023; 119: 504-13. |
[1] | LIANG Xiao, ZHANG Li, CHEN Junlu, DU Yuhan, JIANG Min, FAN Lijie, MA Huirong, DUAN Yancang, SONG Xuping, WANG Xiaohui, DU Huilan. International standard of Traditional Chinese Medicine techniques: clinical guidelines for dysmenorrhea (2022) [J]. Journal of Traditional Chinese Medicine, 2024, 44(6): 1277-1287. |
[2] | YU Siyun, ZHANG Shiwen, XIA Yu, LIU Xiaoqing, LIU Yajie, FU Jinrong. Network-based pharmacology and experimental validation to explore the mechanism of action of the Jiawei Pentongling formula (加味盆痛灵方) for the treatment of endometriosis-related pain [J]. Journal of Traditional Chinese Medicine, 2024, 44(5): 991-999. |
[3] | JIANG Wenjing, JIANG Huaying, YUAN Lihua, SA Yuanhong, XIAO Jimei, SUN Hongqi, SONG Jingyan, SUN Zhengao. Xiaoyi Yusi decoction (消异育嗣汤) improves in vitro fertilization and embryo transfer outcomes in patients with endometriosis [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 1026-1033. |
[4] | YAO Zouying;WANG Jing;LU Hua;LI Limin;ZHUO Tianxiu;WAN Qian;YIE Shangmian;. Zichong granules(资冲颗粒)promote differentiation of ovarian granulosa-like cells from human embryonic stem cells in vitro [J]. Journal of Traditional Chinese Medicine, 2021, 41(2): 203-211. |
[5] | Hu Hantong, Chen Lifang, Jin Xiaofei, Li Ru, Fang Jianqiao. Effect of herb-partitioned moxibustion on pain and quality of life in women with endometriosis: a protocol for a randomized clinical trial [J]. Journal of Traditional Chinese Medicine, 2020, 40(2): 324-332. |
[6] | Zhang Zhijie, Liu Shaoming, Zhang Yueyang, Yang Jingzhe, Kong Tao, Wang Chengli, Ning Peng, Chen Xiaochao, Li Xuesong, Jia Yusen, Chen Xiaojun. Traditional Chinese Medicine syndrome elements of male infertility revealed by latent tree model analysis [J]. Journal of Traditional Chinese Medicine, 2018, 38(06): 926-935. |
[7] | Xia Wanting, Zhong Yanmei, Zhang Ying, Xue Huarong, Huang Jinzhu, Wang Zhen, Zhou Hang, Ma Qianhong, Zeng Qian. Curative effect of assisted reproduction technology by Traditional Chinese Medicine multi-channel interventional therapy on 95 cases of in vitro fertilization and embryo transfer failure [J]. Journal of Traditional Chinese Medicine, 2017, 37(05): 681-687. |
[8] | Gao Hui, Xia Tian, Ma Ruihong, Zhao Zhimei, Song Xueru, Wang Baojuan, Liu Lijing, Han Kaimei, Wang Guoqing, Fu Yu, Hao Guimin. Heyan Kuntai capsule versus dehydroepiandrosterone in treating Chinese patients with infertility caused by diminished ovarian reserve: a multicenter, randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2017, 37(04): 530-537. |
[9] | Huang Yanhui, Shen Lin, Cai Anhe, Xiao Jing. Effect of warming Yang and removing blood stasis method on matrix metalloproteinases/tissue inhibitor metalloproteinases levels secreted by cultured endometrial cells from patients with endometriosis [J]. Journal of Traditional Chinese Medicine, 2015, 35(05): 571-576. |
[10] | Chen Jingwei, Du Huilan, Tong Ruixiao, Yang Hua, Ma Huirong. Effect of Bushenwenyanghuayu decoction on nerve growth factor and bradykinin/bradykinin B_1 receptor in a endometriosis dysmenorrhea mouse model [J]. Journal of Traditional Chinese Medicine, 2015, 35(02): 184-191. |
[11] | Shaofang Peng, Yanping Zheng, Kangzhuang Zheng, Ke Lin, Juhong Wu, Wenqin Zheng, Yongzhong Li, Yang Li, Chuangjian Lin. Effect of a comprehensive therapy plus Gushenyutai plaster administered at Guanyuan(CV 4) on male infertility associated with semen non-liquefaction [J]. Journal of Traditional Chinese Medicine, 2014, 34(06): 666-672. |
[12] | Du Gao, Yun Cui, Jun Wu, Fan Zhang, Yang Zhou. Effect of Traditional Chinese Medicine on oligoasthenospermatism:a narrative review [J]. Journal of Traditional Chinese Medicine, 2014, 34(05): 616-620. |
[13] | Jia Guo, Dong Li, Cheng Liu, Xiao lanJi, Rong Li, Xiao guo DU. Effects of Chinese herbs combined with in vitro fertilization and embryo transplantation on infertility:a clinical randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2014, 34(03): 267-273. |
[14] | Baozhen Pang, Qingyang Pang, Huiqing Pang, Guohong Song. Clinical effect of Jiutengzhuyu tablets on promoting blood circulation in women with oviducal obstruction [J]. Journal of Traditional Chinese Medicine, 2012, 32(04): 549-553. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
Sponsored by China Association of Chinese Medicine
& China Academy of Chinese Medical Sciences
16 Nanxiaojie, Dongzhimen Nei, Beijing, China. 100700 Email: jtcmen@126.com
Copyright 2020 Journal of Traditional Chinese Medicine. All rights reserved.